Cell Source Inc (CLCS) 1.2500 $CLCS
Cell Source names Dr Dennis Brown as board chairman
M2 - Thu Aug 20, 3:52AM CDT
Biotechnology company Cell Source(OTC BB:CLCS) reported on Wednesday it has appointed Dr Dennis Brown as the chairman of its board of directors.
Cell Source Appoints Dr. Dennis Brown as Chairman of Its Board of Directors
Marketwired - Wed Aug 19, 8:04AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Dennis Brown, currently a Director of Cell Source, has been appointed Chairman of the Board of Directors.
American CryoStem Enters Into Agreement to License ATGRAFT Adipose Tissue Storage Platform in Japan
Marketwired - Wed Jul 22, 8:02AM CDT
American CryoStem Corporation (OTC PINK: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the further expansion of its global footprint of its cellular technology and laboratory processing platform by entering into an agreement to license its ATGRAFT(TM) adipose tissue (fat) processing and storage technologies with Cell Source (CS), a Japan based corporation. CS currently operates a cellular processing and banking facility along with an established chain of surgery centers, offering cosmetic, plastic and orthopedic procedures to patients throughout Japan.
Cell Source Appoints Dr. Robert Negrin to Its Scientific Advisory Board
Marketwired - Mon Jul 06, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Robert S. Negrin, Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University, has joined its Scientific Advisory Board.
Cell Source Appoints Dr. Steven Burakoff to Its Scientific Advisory Board
Marketwired - Mon Jun 29, 7:30AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, has joined its Scientific Advisory Board.
World Class Immunologist Dr. Herman Waldmann Joins Cell Source's Scientific Advisory Board
Marketwired - Wed Jun 17, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Herman Waldman, who served as Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford's Therapeutic Antibody Centre, has joined the Cell Source Scientific Advisory Board.
Cell Source names Dr Terry Strom as SAB chair
M2 - Fri Jun 05, 4:52AM CDT
Biotechnology company Cell Source (OTCBB:CLCS) revealed on Thursday the addition of Dr Terry Strom as chairman of its Scientific Advisory Board (SAB).
Cell Source Appoints Dr. Terry Strom as Chairman of Its Scientific Advisory Board
Marketwired - Thu Jun 04, 10:22AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Terry Strom, Professor of Medicine and Surgery at Harvard Medical School and Director of The Transplant Institute at Beth Israel Deaconess Medical Center, has been retained to serve as Chairman of its Scientific Advisory Board.
Cell Source to Present at the 2015 Marcum MicroCap Conference
Marketwired - Fri May 22, 1:01PM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28th, 2015 in New York City at the Grand Hyatt Hotel.
Cell Source, Inc. Announces the Launch of Its New Investor Relations Website
Marketwire Canada - Fri May 22, 12:52PM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, unveiled its new Investor Relations website. The site, (ir.cell-source.com), incorporates numerous features to make browsing for investment information a much faster and informative experience for the Company's current and potential investors.
Cell Source Retains Strategic Patent Advisor Dr. Michael B. Farber
ACCESSWIRE - Wed May 20, 7:30AM CDT
NEW YORK, NY / ACCESSWIRE / May 20, 2015 / Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Michael B. Farber, a Partner with Ditthavong & Steiner P.C. has been retained as Strategic Patent Advisor to the Company. The company's patented "Veto Cell" technology, is licensed exclusively from Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science in Israel.
Cell Source to Present at the Roth Capital Conference in Dana Point, CA on March 10, 2015
ACCESSWIRE - Mon Mar 09, 10:22PM CDT
TEL AVIV, ISRAEL / ACCESSWIRE / March 9, 2015 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Roth Conference on Tuesday, March 10, 2015 at 5:30pm in Dana Point, California.
Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials
PR Newswire - Thu Nov 13, 3:00AM CST
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source" an immunotherapy and regenerative medicine company, announced today its Megadose Drug Combination has been cleared for human clinical trials in Italy. Cell Source's proprietary Megadose Drug Combination is expected to increase bone marrow transplantation (BMT) success and survival. By combining an established cell therapy with U.S. Food and Drug Administration (FDA) approved drugs, Megadose Drug Combination, based on preclinical results to date, may have the potential to enable an improvement in the effectiveness and safety of use of mismatched BMT. BMT is most often used for the treatment of blood cancers and is currently reserved mostly for patients with life threatening diseases, due to complications including transplant rejection. Should BMT become safer, the procedure's use may well be expanded beyond cancer to other indications including genetic and autoimmune disease.
Cell Source names Dr Dennis Brown as board chairman
M2 - Thu Aug 20, 3:52AM CDT
Biotechnology company Cell Source(OTC BB:CLCS) reported on Wednesday it has appointed Dr Dennis Brown as the chairman of its board of directors.
Cell Source Appoints Dr. Dennis Brown as Chairman of Its Board of Directors
Marketwired - Wed Aug 19, 8:04AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Dennis Brown, currently a Director of Cell Source, has been appointed Chairman of the Board of Directors.
American CryoStem Enters Into Agreement to License ATGRAFT Adipose Tissue Storage Platform in Japan
Marketwired - Wed Jul 22, 8:02AM CDT
American CryoStem Corporation (OTC PINK: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced the further expansion of its global footprint of its cellular technology and laboratory processing platform by entering into an agreement to license its ATGRAFT(TM) adipose tissue (fat) processing and storage technologies with Cell Source (CS), a Japan based corporation. CS currently operates a cellular processing and banking facility along with an established chain of surgery centers, offering cosmetic, plastic and orthopedic procedures to patients throughout Japan.
Cell Source Appoints Dr. Robert Negrin to Its Scientific Advisory Board
Marketwired - Mon Jul 06, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Robert S. Negrin, Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University, has joined its Scientific Advisory Board.
Cell Source Appoints Dr. Steven Burakoff to Its Scientific Advisory Board
Marketwired - Mon Jun 29, 7:30AM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai, has joined its Scientific Advisory Board.
World Class Immunologist Dr. Herman Waldmann Joins Cell Source's Scientific Advisory Board
Marketwired - Wed Jun 17, 7:31AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Herman Waldman, who served as Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford's Therapeutic Antibody Centre, has joined the Cell Source Scientific Advisory Board.
Cell Source names Dr Terry Strom as SAB chair
M2 - Fri Jun 05, 4:52AM CDT
Biotechnology company Cell Source (OTCBB:CLCS) revealed on Thursday the addition of Dr Terry Strom as chairman of its Scientific Advisory Board (SAB).
Cell Source Appoints Dr. Terry Strom as Chairman of Its Scientific Advisory Board
Marketwired - Thu Jun 04, 10:22AM CDT
Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Terry Strom, Professor of Medicine and Surgery at Harvard Medical School and Director of The Transplant Institute at Beth Israel Deaconess Medical Center, has been retained to serve as Chairman of its Scientific Advisory Board.
Cell Source to Present at the 2015 Marcum MicroCap Conference
Marketwired - Fri May 22, 1:01PM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28th, 2015 in New York City at the Grand Hyatt Hotel.
Cell Source, Inc. Announces the Launch of Its New Investor Relations Website
Marketwire Canada - Fri May 22, 12:52PM CDT
Cell Source, Inc. (OTCQB: CLCS), a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, unveiled its new Investor Relations website. The site, (ir.cell-source.com), incorporates numerous features to make browsing for investment information a much faster and informative experience for the Company's current and potential investors.
Cell Source Retains Strategic Patent Advisor Dr. Michael B. Farber
ACCESSWIRE - Wed May 20, 7:30AM CDT
NEW YORK, NY / ACCESSWIRE / May 20, 2015 / Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Michael B. Farber, a Partner with Ditthavong & Steiner P.C. has been retained as Strategic Patent Advisor to the Company. The company's patented "Veto Cell" technology, is licensed exclusively from Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science in Israel.
Cell Source to Present at the Roth Capital Conference in Dana Point, CA on March 10, 2015
ACCESSWIRE - Mon Mar 09, 10:22PM CDT
TEL AVIV, ISRAEL / ACCESSWIRE / March 9, 2015 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Roth Conference on Tuesday, March 10, 2015 at 5:30pm in Dana Point, California. Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials
PR Newswire - Thu Nov 13, 3:00AM CST
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its Megadose Drug Combination has been cleared for human clinical trials in Italy. Cell Source's proprietary Megadose Drug Combination is expected to increase bone marrow transplantation (BMT) success and survival. By combining an established cell therapy with U.S. Food and Drug Administration (FDA) approved drugs, Megadose Drug Combination, based on preclinical results to date, may have the potential to enable an improvement in the effectiveness and safety of use of mismatched BMT. BMT is most often used for the treatment of blood cancers and is currently reserved mostly for patients with life threatening diseases, due to complications including transplant rejection. Should BMT become safer, the procedure's use may well be expanded beyond cancer to other indications including genetic and autoimmune disease. 
